Silk Road Medical, Inc

Equities

SILK

US82710M1009

Medical Equipment, Supplies & Distribution

Real-time Estimate Cboe BZX 07:24:49 18/06/2024 pm IST 5-day change 1st Jan Change
26.8 USD +23.65% Intraday chart for Silk Road Medical, Inc +20.97% +118.38%
LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
Correction to Boston Scientific to Buy Silk Road Article DJ
Sector Update: Health Care Stocks Flat to Lower Premarket Tuesday MT
Traders Digest Retail Sales Data Ahead of Holiday Break, Driving Muted Premarket Action for US Equity Futures MT
Sector Update: Health Care MT
Top Premarket Gainers MT
Boston Scientific to Acquire Silk Road Medical for $27.50 Per Share MT
Silk Road Medical Shares Surge Premarket on Boston Scientific Deal DJ
Boston Scientific to Buy Silk Road Medical for About $1.26 Billion DJ
Boston Scientific Announces Agreement to Acquire Silk Road Medical RE
Silk Road Medical to Be Acquired by Boston Scientific in $1.26 Billion Deal MT
Boston Scientific to buy Silk Road Medical for $1.16 billion RE
Boston Scientific Announces Agreement to Acquire Silk Road Medical, Inc CI
Transcript : Silk Road Medical, Inc Presents at Bank of America Health Care Conference 2024, May-14-2024 through May-16-2024
Transcript : Silk Road Medical, Inc, Q1 2024 Earnings Call, Apr 30, 2024
Earnings Flash (SILK) SILK ROAD MEDICAL Reports Q1 Revenue $48.5M, vs. Street Est of $44.7M MT
Silk Road Medical, Inc Provides Revenue Guidance for the Year 2024 CI
Silk Road Medical, Inc Provides Revenue Guidance for the Full Year 2024 CI
Silk Road Medical, Inc Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Silk Road Medical Strengthens TCAR Portfolio with Launch of ENROUTE Transcarotid Neuro Protection System Plus CI
North American Morning Briefing : Stock Futures -2- DJ
Silk Road Medical Inc. and Genesis MedTech Group have signed an exclusive distribution agreement to introduce the TCAR® core products CI
Argus Upgrades Silk Road Medical to Buy From Hold, Price Target is $24 MT
Silk Road Medical Expands TCAR Portfolio with Launch of Tapered Enroute®? Transcarotid Stent System CI
Piper Sandler Raises Price Target on Silk Road Medical to $18 From $11, Maintains Neutral Rating MT
Transcript : Silk Road Medical, Inc, Q4 2023 Earnings Call, Feb 28, 2024
Chart Silk Road Medical, Inc
More charts
Silk Road Medical, Inc. is a medical device company that is focused on reducing the risk of stroke and its impact. The Company has developed an approach for the treatment of carotid artery disease called TransCarotid Artery Revascularization (TCAR). TCAR is a clinically proven procedure combining surgical principles of neuroprotection with minimally invasive endovascular techniques to treat blockages in the carotid artery at risk of causing a stroke. Its product portfolio consists of five single-use components: ENROUTE Transcarotid Neuroprotection System, ENROUTE Transcarotid Stent System, ENHANCE Transcarotid Peripheral Access Kit, ENROUTE 0.014'' Guidewire and ENROUTE Enflate Transcarotid RX Balloon Dilation Catheter. It manufactures ENROUTE NPS and ENROUTE NPS PLUS, or its ENROUTE NPS products, at its facilities in Sunnyvale, California and Plymouth, Minnesota. These facilities provide an aggregate of over 35,000 square feet of space for its production and distribution operations.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
9
Last Close Price
21.67 USD
Average target price
20.83 USD
Spread / Average Target
-3.86%
Consensus